Vivos (RDGL) 10-K24 Mar 212020 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2020	Mar. 18, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	VIVOS INC
Entity Central Index Key	0001449349
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 7,045,405
Entity Common Stock, Shares Outstanding		297,346,254
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 903,704	$ 20,381
Prepaid expenses	33,835	23,492
Total Current Assets	937,539	43,873
TOTAL ASSETS	937,539	43,873
Current Liabilities:
Accounts payable and accrued expenses	361,880	511,817
Related party accounts payable	32,110	32,110
Accrued interest payable	100,954	93,249
Payroll liabilities payable	66,143	100,000
Convertible notes payable, related party, net		14,500
Convertible notes payable, net	107,418	434,886
Promissory notes payable, net of discount		100,000
Related party promissory note	237,000	237,000
Total Current Liabilities	905,505	1,523,562
Total Liabilities	905,505	1,523,562
Commitments and contingencies
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, par value, $0.001, 950,000,000 shares authorized, 292,278,591 and 184,845,821 issued and outstanding, respectively	292,279	184,846
Additional paid in capital - common stock	64,551,764	61,721,809
Accumulated deficit	(74,558,101)	(73,601,109)
Total Stockholders' Equity (Deficit)	32,034	(1,479,689)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	937,539	43,873
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	2,171	2,553
Additional paid in capital - preferred stock	8,857,358	8,870,626
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	436	1,113
Additional paid in capital - preferred stock	385,235	665,195
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	385	821
Additional paid in capital - preferred stock	$ 500,507	$ 674,457

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	292,278,591	184,845,821
Common stock, shares outstanding	292,278,591	184,845,821
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,171,007	2,552,642
Preferred stock, shares outstanding	2,171,007	2,552,642
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	436,653	1,113,245
Preferred stock, shares outstanding	436,653	1,113,245
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	385,302	821,292
Preferred stock, shares outstanding	385,302	821,292

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues, net	$ 7,000	$ 9,500
Cost of Goods Sold	(5,608)	(6,028)
Gross profit	1,392	3,472
OPERATING EXPENSES
Professional fees	243,942	462,952
Stock based compensation	2,176	608,588
Payroll expenses	234,094	120,000
Research and development	84,668	67,584
General and administrative expenses	109,033	74,327
Total Operating Expenses	673,913	1,333,451
OPERATING LOSS	(672,521)	(1,329,979)
NON-OPERATING INCOME (EXPENSE)
Interest expense	(287,471)	(261,374)
Other income - SBA	3,000
Loss on debt extinguishment		(18,744)
Total Non-Operating Income (Expenses)	(284,471)	(280,118)
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(956,992)	(1,610,097)
Provision for income taxes
NET LOSS	$ (956,992)	$ (1,610,097)
Net loss per share - basic and diluted	$ 0	$ (0.01)
Weighted average common shares outstanding - basic	222,804,039	175,195,600

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity (Deficit) - USD ($)	Series A Preferred [Member]	Additional Paid-In Capital - Series A Preferred [Member]	Series B Preferred [Member]	Additional Paid-In Capital - Series B Preferred [Member]	Series C Preferred [Member]	Additional Paid-In Capital - Series C Preferred [Member]	Common Stock [Member]	Additional Paid-In Capital - Common [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 2,553	$ 8,870,626	$ 3,306	$ 1,876,768			$ 163,446	$ 60,132,139	$ (71,991,012)	$ (942,174)
Balance, shares at Dec. 31, 2018	2,552,642		3,305,755				163,445,736
Stock issued for: Cash			$ 100	49,900			$ 1,250	48,750		100,000
Stock issued for: Cash, shares			100,000				1,250,000
Stock issued for: Accounts payable							$ 1,063	42,837		43,900
Stock issued for: Accounts payable, shares							1,062,500
Stock issued for: Services							$ 312	12,188		12,500
Stock issued for: Services, shares							312,500
Adjustment for fractional shares in reverse split
Adjustment for fractional shares in reverse split, Shares							(140)
Conversion of restricted stock units into common stock							$ 385	(385)
Conversion of restricted stock units into common stock, shares							385,000
Conversion of preferred stock into common stock			$ (1,472)	(587,016)			$ 18,390	570,098
Conversion of preferred stock into common stock, shares			(1,471,218)				18,390,225
Conversion of Series B Preferred into Series C Preferred			$ (821)	(674,457)	$ 821	674,457
Conversion of Series B Preferred into Series C Preferred, Shares			(821,292)		821,292
Warrants issued with notes payable (discount)								151,049		151,049
Warrants issued in settlement of litigation								18,500		18,500
Warrants issued for extension of notes payable								25,656		25,656
Options issued for settlement of accounts payable								48,641		48,641
Options and warrants issued for services								612,379		612,379
BCF recognized on convertible notes								59,957		59,957
Net loss for the year									(1,610,097)	(1,610,097)
Balance at Dec. 31, 2019	$ 2,553	8,870,626	$ 1,113	665,195	$ 821	674,457	$ 184,846	61,721,809	(73,601,109)	(1,479,689)
Balance, shares at Dec. 31, 2019	2,552,642		1,113,245		821,292		184,845,821
Stock issued for: Cash							$ 60,618	1,576,062		1,636,680
Stock issued for: Cash, shares							60,617,778
Conversion of preferred stock into common stock			$ (577)	(230,060)	$ (436)	(173,950)	$ 12,657	392,366
Conversion of preferred stock into common stock, shares			(576,592)		(435,990)		12,657,275
Warrants issued with notes payable (discount)								28,482		28,482
Options and warrants issued for services								80,059		80,059
Stock issued for: Note conversion/settlements							$ 25,965	675,079		701,044
Stock issued for: Note conversion/settlements, shares							25,964,594
Stock issued for: Warrant exercises							$ 8,193	51,807		60,000
Stock issued for: Warrant exercises, shares							8,193,185
Redemption of preferred stock in convertible note agreement			$ (100)	(49,900)						(50,000)
Redemption of preferred stock in convertible note agreement, shares			(100,000)
Redemption of preferred stock for cash	$ (382)	(13,268)								(13,650)
Redemption of preferred stock for cash, shares	(381,635)
Warrants purchased for cash								26,100		26,100
Share adjustment
Share adjustment, shares							(62)
Net loss for the year									(956,992)	(956,992)
Balance at Dec. 31, 2020	$ 2,171	$ 8,857,358	$ 436	$ 385,235	$ 385	$ 500,507	$ 292,279	$ 64,551,764	$ (74,558,101)	$ 32,034
Balance, shares at Dec. 31, 2020	2,171,007		436,653		385,302		292,278,591

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CASH FLOW FROM OPERTING ACTIVIITES
Net loss	$ (956,992)	$ (1,610,097)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of convertible debt discount	53,527	134,034
Amortization of BCF discount	6,187	55,740
Common stock issued for services		12,500
Stock options and warrants for services	2,176	612,379
Forgiveness of debt		(34,106)
Warrants issued for interest expense	77,883	25,656
Exchange premium in conversion of notes	98,508
Changes in assets and liabilities
Prepaid expenses and other assets	(10,343)	(12,500)
Accounts payable and accrued expenses	(149,937)	(136,371)
Accounts payable and accrued expenses from related party		(6,500)
Payroll liabilities	(33,857)	88,549
Accrued interest	37,041	33,603
Total adjustments	81,185	772,984
Net cash used in operating activities	(875,807)	(837,113)
CASH FLOWS FROM FINANCING ACTIVITES
Proceeds from related party notes payable		237,000
Redemption of preferred stock	(63,650)
Proceeds from sale of preferred stock		50,000
Proceeds from sale of common stock		50,000
Proceeds from sale of common stock and warrants	1,662,780
Proceeds from the exercise of stock options	60,000
Proceeds from convertible debt	150,000	500,000
Proceeds from promissory notes - related party, net of repayments		15,000
Payment of notes payable	(50,000)
Net cash provided by financing activities	1,759,130	852,000
NET INCREASE IN CASH	883,323	14,887
CASH - BEGINNING OF YEAR	20,381	5,494
CASH - END OF YEAR	903,704	20,381
CASH PAID DURING THE PERIOD FOR:
Interest expense	13,442	4,000
Income taxes
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:
Cashless exercise of warrants	5,693
Conversion of preferred stock into common stock	405,023	588,487
Conversion of convertible preferred B into convertible preferred C		675,278
Recognition of debt discount at inception of notes payable	28,482	151,048
Conversion of notes payable and accrued interest into common stock	701,044
Recognition of BCF discount at inception of notes payable		59,957
Common stock issued in settlement of accounts payable		43,900
Stock options issued in settlement of accounts payable		48,643
Reclassification of notes payable and accrued interest into common stock		15,000
Warrants issued for settlement of litigation		$ 18,500

Organization & Basis of Present

Organization & Basis of Presentation	12 Months Ended
Organization & Basis of Presentation	Dec. 31, 2020
Accounting Policies [Abstract]
Organization & Basis of Presentation	NOTE 1: ORGANIZATION & BASIS OF PRESENTATION Business Overview Vivos Inc. (the “ Company SMSC Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.” The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel TM FDA ® Based on the FDA’s recommendation, RadioGel TM ® ® ® TM ® TM TM” IsoPet Solutions The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017. The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“ RECIST The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy. The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program. The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with GAAP. Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019. Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA Y-90 Recently, the Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication. The Company’s lead brachytherapy products, including RadioGel™, incorporate patented technology developed for Battelle Memorial Institute (“ Battelle Battelle License The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet® and Radiogel™. As part of the normal review process, we have also submitted the technical justification for seven additional claims. We are in the process of filing patent claims in Canada, UK (Great Britain, Scotland, Wales and Ireland), Japan, Germany, Italy, France, Australia, Brazil, China, India, North Countries (Sweden, Norway, Finland, and Denmark). Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2 million annually to maintain current operating activities. The Company has completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019. The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020 and have issued the first tranche of shares under the Regulation A+ on June 10, 2020. The intent is to raise up to $1,800,000 over the next 12-18 months, which may be completed in separate closings. The Company intends to use the proceeds generated from the sale of shares under Regulation A+ as follows: For the animal therapy market: ● Fund the effort to communicate the benefits of IsoPet ® ● Conduct additional clinical studies to generate more data for the veterinary community ● Subsidize some IsoPet ® ● Assist a new regional clinic with their license and certification training. For the human market: ● Enhance the pedigree of the Quality Management System. ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting. ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials. The Company received $497,880 which were deposited into the Company’s accounts between April and June 2020. Following the clearance of the Regulation A+ offering by the SEC on June 3, 2020, the common shares for these proceeds were issued. In addition, the Company exchanged their outstanding convertible notes payable of $525,000, $27,536 in accrued interest and $98,508 in an exchange premium stipulated in the note agreements into shares of common stock. In addition, the Company raised $1,138,800 in the Regulation A+ from November 30, 2020 through December 3, 2020 and issued 42,177,778 shares of common stock and sold 19,200,000 warrants for $19,200 in these offerings. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company requires funding of approximately $2 million annually to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet ® The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises. Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States, the initial epicenter of the COVID-19 outbreak in the United States. In addition to a slow down in the marketing of the services, the volatility of the stock market has contributed to a lack of funds that ordinarily may have been available to the Company. The Company is hopeful that by the end of the third quarter of 2021, they will be allowed to continue their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly. As of December 31, 2020, the Company has $903,704 cash on hand. There are currently commitments to vendors for products and services purchased that will necessitate liquidation of the Company if it is unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company. Assuming the Company is successful in the Company’s sales/development effort, it believes that it will be able to raise additional funds through strategic agreements or the sale of the Company’s stock to either current or new stockholders. There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these audited financial statements so as to conform to current period classifications. Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material. Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2020 and 2019, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis. Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date. Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down. License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%). Future minimum royalties for the years ended December 31 are noted below: Minimum Royalties per Calendar Year Calendar Year 2021 $ 10,000 2022 4,000 Total $ 14,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The 2021 fee was paid in December 2020. Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the years ended December 31, 2020 and 2019, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. The Company recognized revenue as they (i) identified the contracts with ach customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue generated during the years ended December 31, 2020 and 2019 related to sales of product. Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2020 and 2019, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2020 and 2019, which include the following: December 31, 2020 December 31, 2019 Convertible debt 1,252,456 10,914,782 Preferred stock 12,998,195 27,372,515 Common stock options 28,885,461 34,524,580 Common stock warrants 32,064,375 31,286,847 Total potential dilutive securities 75,190,487 104,098,724 Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $84,668 and $67,584 research and development costs for the years ended December 31, 2020 and 2019, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the years then ended. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2020 and 2019, the Company incurred $6,182 and $0 in advertising and marketing costs which are included in general and administrative expenses. Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2020 and 2019. Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2020 and 2019. The Company did not have any deferred tax liability or asset on its balance sheet on December 31, 2020 and 2019. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2020 and 2019, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. Stock-Based Compensation The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. The Company has determined that no amounts had to be revalued upon adoption of this amendment. Recent Accounting Pronouncements In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Fixed Assets

Fixed Assets	12 Months Ended
Fixed Assets	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Fixed Assets	NOTE 3: FIXED ASSETS Fixed assets consist of the following at December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Production equipment $ - $ - Less accumulated depreciation - - $ - $ - There is no depreciation expense for the years ended December 31, 2020 and 2019. In June 2019, the Company sold the one piece of equipment still held for $0. The basis of this piece of equipment was also $0, resulting in no gain or loss on the sale.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 4: RELATED PARTY TRANSACTIONS Related Party Convertible Notes Payable As of December 31, 2020 and 2019, the Company had the following related party convertible notes outstanding: 2020 2019 September 2019 $15,000 Note, 8% interest, due January 2020 $ - $ 15,000 - - Total Convertible Notes Payable, Net $ - $ 15,000 Less: Debt Discount - (500 ) $ - $ 14,500 The Company from time to time receives non-interest bearing advancers from its Chief Executive Officer that are due on demand. During the year ended December 31, 2019, the Company received $20,000 in advances and repaid $5,000 of these and had $15,000 outstanding at September 24, 2019. On September 24, 2019, these advances were converted into a convertible note at 8% interest which matures January 15, 2020. Interest on this note for the period ended December 31, 2019 amounted to $321, and this amount is accrued at December 31, 2019. The Chief Executive Officer received 150,000 warrants when the advances were converted into this convertible note payable. The Company recognized a discount on the convertible note of $3,721 as a result of the warrants which are being amortized over the life of the note through January 15, 2020. The Company is in default of this note. As a result of the default, the interest rate charged was changed to 12.5% through conversion of this note in April 2020. Interest expense for the years ended December 31, 2020 and 2019 on the related party convertible notes payable amounted to $298 and $321, respectively. Related Party Notes Payable As of December 31, 2020 and 2019, the Company had the following related party notes outstanding: 2020 2019 January 2019 $60,000 Note, 8% interest, due January 2020 $ 60,000 $ 60,000 March 2019 $48,000 Note, 8% interest, due March 2020 48,000 48,000 April 2019 $29,000 Note, 8% interest, due April 2020 29,000 29,000 July 2019 $50,000 Note 8% interest, due July 2020 50,000 50,000 November 2019 $50,000 Note 8% interest, due November 2020 50,000 50,000 Total Related Party Notes Payable, Net $ 237,000 $ 237,000 On January 24, 2019 the Company entered into a note payable with a trust related to one of the Company’s directors in the amount of $60,000. The note is for a one-year period which was to mature January 24, 2020 and bears interest at an annual rate of 8.00%. The Company is in default of this note. On March 27, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $48,000. The note is for a one-year period maturing March 27, 2020 and bears interest at an annual rate of 8%. The Company is in default of this note. On April 29, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $29,000. The Company is in default of this note. On July 5, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $50,000. The note is for a one-year period maturing July 5, 2020 and bears interest at an annual rate of 8%. The Company is in default of this note. On November 25, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $50,000. The note is for a one-year period maturing November 25, 2020 and bears interest at an annual rate of 8%. The Company is in default of this note. Interest expense for these notes for the years ended December 31, 2020 and 2019 was $18,960 and $11,307, respectively and accrued interest at December 31, 2020 is $30,267. The Company borrowed $107,000 in the year ended December 31, 2020 from its CEO and repaid these amounts in full. Related Party Payables The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s behalf. As a result of these activities the Company had related party payables of $32,110 and $32,110 as of December 31, 2020 and 2019, respectively. Preferred and Common Shares Issued to Officers and Directors The Company’s Chairman converted the Series B Convertible Preferred Shares into Series C Convertible Preferred Shares and as of April 2020, the 385,302 shares that are issued in the Series C Convertible Preferred Stock are all to the Chairman. In April 2020, effective March 31, 2020, the Company converted the $15,000 convertible note payable along with $619 in accrued interest and an exchange premium of $3,124 into 694,178 shares of common stock. This was part of the Regulation A+. These shares were issued on June 10, 2020 following the qualification of the Regulation A+. The Company’s Chief Executive Officer exercised 2,500,000 stock options for $60,000 in December 2020.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
Convertible Notes Payable	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5: CONVERTIBLE NOTES PAYABLE As of December 31, 2020 and 2019, the Company had the following convertible notes outstanding: 2020 2019 July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 45,000 May 2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019 - 60,000 July 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 38,000 September 2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 25,000 September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 37,000 December 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due March 31, 2020 - 50,000 November 2020 $50,000 Note convertible into common shares at $0.04, 6% interest, due May 30, 2021 50,000 - Penalties on notes in default 12,418 10,618 Total Convertible Notes Payable, Net $ 107,418 $ 465,618 Less: BCF Discount - (6,187 ) Less: Debt Discount - (24,545 ) $ 107,418 $ 434,886 Interest expense for the years ended December 31, 2020 and 2019 on the convertible notes payable amounted to $21,394 and $16,563, respectively. The Company entered into a $50,000 convertible promissory note dated May 31, 2019, that was to mature October 30, 2019. The convertible promissory note bears interest at a rate of 8%, The convertible promissory note is convertible into shares of common stock at a price of $0.032 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory note together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The $10,000 contingent exchange amount is classified as original issue discount and will be amortized over the life of the convertible promissory note. The convertible promissory noteholder received 625,000 warrants at an exercise price of $0.04 per share, that have a term of two years. The warrants were valued at $12,592 and represent a debt discount, which were amortized over the life of the convertible promissory note. The Company entered into $300,000 in convertible promissory notes in July and September 2019, that were to mature January 15, 2020. The convertible promissory notes bear interest at a rate of 8%, The convertible promissory notes are convertible into shares of common stock at a price of $0.04 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory notes together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The convertible promissory noteholders received 3,000,000 warrants at an exercise price ranging between $0.06 and $0.08 per share (amended to $0.045 per share), that have a term of two years. The warrants were valued at $91,716 and represent a debt discount, which will be amortized over the life of the convertible promissory notes. In addition, the Company recognized a beneficial conversion feature discount to the notes of $59,957 that is being amortized over the life of the notes. Prior to the conversion of these notes, the Company was in default of these notes. As a result of the default, the interest rate charged was changed to 12.5% up through the conversion of these notes. The Company entered into $50,000 in a convertible promissory note on December 31, 2019, that matures March 31, 2020. The convertible promissory notes bear interest at a rate of 8%, The convertible promissory note is convertible into shares of common stock at a price of $0.04 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory notes together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The convertible promissory noteholders received 625,000 warrants at an exercise price of $0.06 per share (amended to $0.045 per share), that have a term of two years. The warrants were valued at $14,299 and represent a debt discount, which will be amortized over the life of the convertible promissory note. This note was converted effective March 31, 2020. These shares were issued on June 10, 2020 following the qualification of the Regulation A+. The Company issued a convertible note in January 2020 in the amount of $100,000 to an accredited investor. The note bears interest at 8% per annum and was to mature March 31, 2020. The Company granted 1,250,000 warrants with an exercise price of $0.06 per share and a term of two years with this note and amended 1,312,500 previously issued warrants held by the investor to provide for a $.06 exercise price and an expiration date of March 31, 2022, the note was converted in June 2020. The Company entered into a $50,000 convertible promissory note on November 30, 2020, that matures May 30, 2021. The convertible promissory notes bear interest at a rate of 6%, The convertible promissory note is convertible into shares of common stock at a price of $0.04 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $350,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory notes together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The Company along with the noteholder agreed to exchange 1,867,500 warrants into 933,750 common shares. These shares were issued in December 2020.

Promissory Notes Payable

Promissory Notes Payable	12 Months Ended
Promissory Notes Payable	Dec. 31, 2020
Debt Disclosure [Abstract]
Promissory Notes Payable	NOTE 6: PROMISSORY NOTES PAYABLE As of December 31, 2020 and 2019, the Company had the following promissory notes outstanding: 2020 2019 February 2019, two promissory notes for $50,000 each (total of $100,000), maturing August 2019, extended to February 2020, at 8.00% interest (originally) and now 15% interest and extended to August 20, 2020 $ - $ 100,000 Debt discount (- ) - Total Promissory Notes Payable, Net $ - $ 100,000 The Company issued two separate promissory notes on February 20, 2019 at $50,000 each (total of $100,000) that were to mature on August 20, 2019 and accrued interest at 8.00% per annum. In connection with the promissory notes, the Company issued warrants to purchase 1,250,000 shares of common stock. The Company recorded the relative fair value of the warrants as a debt discount of $28,721 and amortized the discount over the life of the note (6 months). Amortization of debt discount for the year ended December 31, 2019 was $28,721 and is recorded as interest expense on the statement of operations for the year ended December 31, 2019. On August 20, 2019, the two noteholders agreed to extend these notes another six-months to February 20, 2020, then amended again for six-months and the notes were to mature August 20, 2020. In consideration for the extension, the note holders received 750,000 warrants (375,000 each) and the interest rate on the notes increased from 8% to 15% per annum. The interest expense on these notes for the years ended December 31, 2020 and 2019 amounted to $8,032 and $9,410. The Company repaid $50,000 of these notes plus $13,442 in accrued interest in July 2020, and settled the remaining $50,000 into 1,851,852 shares of common stock effective July 14, 2020.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 7: INCOME TAXES Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net deferred tax assets consist of the following components as of December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Deferred tax assets: Net operating loss carryover $ 6,080,000 $ 5,890,000 Interest expense - 15,000 Related party accrual 6,400 23,400 Capital Loss Carryover 3,400 3,400 Deferred tax liabilities Depreciation (- ) (2,100 ) Valuation allowance (6,089,800 ) (5,929,700 ) Net deferred tax asset $ - $ - The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2020 and 2019 due to the following: December 31, 2020 December 31, 2019 Book income (loss) $ (201,000 ) $ (338,100 ) Forgiveness of debt (600 ) (7,200 ) Depreciation (1,100 ) (1,100 ) Interest expense - 15,000 Related party accrual 4,000 21,100 Stock for services - 2,600 Options expense 500 134,000 Non-cash interest expense 5,900 39,900 Valuation allowance 192,300 133,800 Income tax expense $ - $ - At December 31, 2020, the Company had net operating loss carryforwards of approximately $28,960,300. Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At the adoption date of January 1, 2007, the Company had no unrecognized tax benefit, which would affect the effective tax rate if recognized. The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2020, the Company had no accrued interest or penalties related to uncertain tax positions. The Company files income tax returns in the U.S. federal jurisdiction. The Company is located in the state of Washington and Washington state does not require the filing of income taxes. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2017.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
Stockholders' Deficit	Dec. 31, 2020
Equity [Abstract]
Stockholders' Deficit	NOTE 8: STOCKHOLDERS’ DEFICIT Common Stock The Company has 950,000,000 shares of common stock authorized, with a par value of $0.001, and as of December 31, 2020 and December 31, 2019, the Company has 292,278,591 and 184,845,821 shares issued and outstanding, respectively. On March 28, 2019, the Company’s board of directors approved a reverse 1-for-8 stock split, and a decrease in the authorized shares from 2,000,000,000 to 950,000,000. The reverse stock split went effective by FINRA on June 28, 2019. Preferred Stock As of December 31, 2020 and 2019, the Company has 20,000,000 shares of Preferred stock authorized with a par value of $0.001. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others. On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares. On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series C Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares. Series A Convertible Preferred Stock (“Series A Convertible Preferred”) In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from 2,500,000 shares to 5,000,000 shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred: Liquidation Preference Dividends Conversion Series A Conversion Shares In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares. Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series B Convertible Preferred Stock (“Series B Convertible Preferred”) In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred: Liquidation Preference Dividends Conversion Series B Conversion Shares Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series C Convertible Preferred Stock (“Series C Convertible Preferred”) In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred: Liquidation Preference Dividends Conversion Series C Conversion Shares The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“ Authorized Share Approval Initial Convertibility Date Conversion Rights Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Common and Preferred Stock Issuances - 2020 The Company in January 2020 paid $50,000 to redeem 100,000 shares of Series B Convertible Preferred Stock. The redemption price was agreed to by the investor. In January 2020, the Company converted 435,990 shares of Series C Convertible Preferred stock into 5,449,875 shares of common stock. In March through June 2020, the Company entered into agreements to issue 18,440,000 shares of common stock conditioned upon the qualification of the offer and sale of such shares under Regulation A+ for $497,880. Additionally, the Company agreed to issue 9,220,000 warrants with a term of two years and an exercise price of $.045 for a purchase price of $8,143. These shares were issued in June 2020 and July 2020 following the qualification of the Regulation A+. In March through June 2020, certain holders of convertible promissory notes entered into agreements to exchange certain notes totaling $651,044, including $525,000 in principal amount, $27,536 in accrued interest and an exchange premium as provided for in the note agreements of $98,508 into 21,770,668 shares of common stock effective upon the qualification of the offer and sale of such shares under Regulation A+. In connection with the holder’s agreement to enter into the exchange, the Company issued 2,200,000 warrants with a two-year term and an exercise price of $0.045 per share and amend 4,400,000 previously issued warrants to provide for a $.045 exercise price and an expiration date of March 31, 2022. These shares were issued on June 10, 2020 following the qualification of the Regulation A+. During the three months ended September 30, 2020, the Company issued 1,851,852 shares of common stock to settle $50,000 in promissory notes. Between November 30 and December 2, 2020, the Company issued 42,177,778 shares of common stock along with 19,200,000 warrants under the Regulation A+ for cash proceeds of $1,138,800 for the common stock and the warrants were purchased for $19,200. On November 30, 2020, the Company issued 933,750 shares of common stock in exchange for 1,867,500 warrants in accordance with a convertible promissory note. On December 2, 2020, holders of Series A Preferred stock redeemed 381,635 shares of Series A Preferred stock for $13,650. The Company canceled these certificates simultaneous to the redemption. On December 3, 2020, a Series B Preferred holder converted 276,592 Series B shares into 3,457,400 common shares, and on December 29, 2020 this Series B Preferred holder converted 300,000 Series B shares into 3,750,000 common shares. On December 10, 2020, the Chief Executive Officer exercised 2,500,000 stock options into common shares valued at $60,000. Between December 14, 2020 and December 28, 2020, the Company issued 4,759,435 shares of common stock in the cashless exercise of 6,860,000 warrants. Common and Preferred Stock Issuances - 2019 In January 2019, the Company received $100,000 in gross proceeds resulting from the issuance to accredited investors of 1,250,000 shares of common stock, 100,000 shares of Series B Convertible Preferred and warrants to purchase 1,250,000 shares of common stock. The Company issued 18,390,225 shares of common stock in consideration for the conversion of 1,471,218 shares of Series B Convertible Preferred. The Company issued 821,292 shares of Series C Convertible Preferred in exchange for 821,292 shares of Series B Convertible Preferred. The Company issued 1,062,500 shares of common stock in a settlement of accounts payable valued at $43,900. This includes 500,000 shares to the Company’s former CEO in settlement of that litigation (see Note 9). The Company issued 312,500 shares of common stock for services rendered in connection with the raising of debt instruments valued at $12,500. The Company issued 385.000 shares of common stock in conversion of vested restricted stock units. Common Stock Options The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests. The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2018 11,318,021 $ 0.11-120.00 3.91 years $ - $ 0.24 Options granted 23,252,809 $ 0.024-0.04 - $ - Options exercised - $ - - $ - Options expired (46,250 ) $ - - $ - Balance at December 31, 2019 34,524,580 $ 0.024-120.00 6.49 years $ 277,973 $ 0.08 Options granted - $ - - $ - Options exercised (2,500,000 ) $ - - $ - Options expired (3,139,119 ) $ - - $ - Balance at December 31, 2020 28,885,461 $ 0.024-120.00 5.57 years $ 1,661,429 $ 0.05 Exercisable at December 31, 2020 28,789,836 $ 0.024-120.00 5.56 years $ 1,653,636 $ 0.05 In June 2019, the Company issued 382,500 stock options to consultants that vest through June 30, 2020. The grant date of these options was June 17, 2019, the date of board approval. On June 21, 2019, 46,250 stock options expired that were issued June 21, 2016. There was $6,529 expensed in 2019 and $2,176 remaining to be expensed through June 30, 2020 for these options. The Company has granted 21,000,000 stock options under the Company’s 2015 Omnibus Securities and Incentive Plan to Dr. Korenko. The granting of the stock options occurs 10 days after the approval of the Company’s recent 1 for 8 reverse stock split that occurred on June 28, 2018. The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019, and December 31, 2019); (ii) 25% upon the Company filing a patent (completed on July 1, 2019); and (iii) 25% upon the first commercial sale of IsoPet ® In September 2019, the Company granted 1,000,000 stock options in a settlement agreement for past due legal fees. The options have a ten-year life and vest immediately. These options were valued at $33,829 which offset accounts payable. The Company recognized a gain of $34,106 on this transaction which is included in the net (gain) loss on debt extinguishment in the statement of operations for the year ended December 31, 2019. In September 2019, the Company granted 500,000 stock options to a consultant for services rendered. The options have a ten-year life and vest immediately. These options were valued at $16,915. In December 2019, the Company granted 370,309 stock options to consultants for accounts payable. The options have a ten-year life and vest immediately. These options were valued at $14,812. On December 10, 2020, the Chief Executive Officer exercised 2,500,000 stock options into common shares valued at $60,000. During the years ending December 31, 2020 and 2019, the Company recognized $2,176 and $608,588, respectively, worth of stock based compensation related to the vesting of it stock options. Common Stock Warrants The following schedule summarizes the changes in the Company’s common stock warrants: Weighted Weighted Warrants Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2018 23,052,472 $ 0.08-80.00 1.77 years $ - $ 0.08 Warrants granted 8,234,375 $ - - $ Warrants exercised - $ - - $ Warrants expired/cancelled - $ - - $ Balance at December 31, 2019 31,286,847 $ 0.08-80.00 0.97 years $ - $ 0.10 Warrants granted 31,870,000 $ 0.045-0.06 - $ Warrants exercised/exchanged (8,727,500 ) $ - - $ Warrants expired/cancelled (22,364,972 ) $ - - $ Balance at December 31, 2020 32,064,375 $ 0.04-80.00 1.65 years $ 1,614,567 $ 0.06 Exercisable at December 31, 2020 32,064,375 $ 0.04-80.00 1.65 years $ 1,614,567 $ 0.06 Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the years ended December 31, 2020 and 2019: Year Ended Year Ended December 31, December 31, Expected term 2 - 5 years 2 - 5 years Expected volatility 109 - 147 % 144 - 295 % Expected dividend yield - - Risk-free interest rate 0.20 - 0.58 % 0.58 – 0.81 % For the year ended December 31, 2019, the Company granted 1,250,000 warrants in the issuance of common and preferred shares issued for cash to accredited investors, 5,650,000 warrants in the issuance of promissory notes (recorded as a debt discount valued at $151,048), 750,000 warrants for the extension of promissory notes, recorded as interest expense valued at $25,656, 500,000 warrants for settlement of accounts payable valued at $18,500 (see Note 9) and 84,375 warrants issued for consulting services valued at $3,792. The Company issued a convertible note in the amount of $100,000 to an accredited investor. The note bears interest at 8% per annum and matures March 31, 2020. The Company granted 1,250,000 warrants with an exercise price of $0.06 per share and a term of two years with this note and amended 1,312,500 previously issued warrants held by the investor to provide for a $.06 exercise price and an expiration date of March 31, 2022. This issuance resulted in a debt discount of $28,482. In March through June 2020, the Company entered into agreements to issue 18,440,000 shares of common stock conditioned upon the qualification of the offer and sale of such shares under Regulation A+ for $497,880. Additionally, the Company agreed to issue 9,220,000 warrants with a term of two years and an exercise price of $.045 for a purchase price of $8,143. These shares were issued in June 2020 and July 2020 following the qualification of the Regulation A+. In March through June 2020, certain holders of convertible promissory notes entered into agreements to exchange certain notes totaling $651,044, including $525,000 in principal amount, $27,536 in accrued interest and an exchange premium as provided for in the note agreements of $98,508 into 21,770,668 shares of common stock effective upon the qualification of the offer and sale of such shares under Regulation A+. In connection with the holder’s agreement to enter into the exchange, the Company issued 2,200,000 warrants with a two-year term and an exercise price of $0.045 per share and amend 4,400,000 previously issued warrants to provide for a $.045 exercise price and an expiration date of March 31, 2022. These shares were issued on June 10, 2020 following the qualification of the Regulation A+. The issuance of the warrants resulted in $77,883 in additional warrant expense. Between November 30, 2020 and December 2, 2020 the Company sold 19,200,000 warrants for $19,200. These warrants have a two-year term and have an exercise price of $0.06 per share. On November 30, 2020, the Company exchanged 1,867,500 warrants into 933,750 shares of common stock, and between December 14, 2020 and December 28, 2020, there were cashless exercises of 6,860,000 warrants into 4,759,435 shares of common stock. In the Company’s quarter ended December 31, 2020, 22,364,972 warrants expired. Restricted Stock Units The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2018 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at December 31, 2019 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at December 31, 2020 262,500 $ 0.59 During the years ended December 31, 2020 and 2019, the Company recognized $0 and $0 worth of expense related to the vesting of its RSU’s, respectively. As of December 31, 2020, the Company had $155,400 worth of expense yet to be recognized for RSU’s not yet vested.

Legal Matters

Legal Matters	12 Months Ended
Legal Matters	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 9: LEGAL MATTERS The Company may, from time to time, be involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. Other than as set forth below, there are no additional material pending or threatened legal proceedings at this time. On January 28, 2019, James Katzaroff, (“ Plaintiff Release Complaint On November 25, 2019, the Company and its current and former directors entered into a Settlement Agreement with the Plaintiff. Under the terms of the Settlement Agreement, the Company has agreed to issue 500,000 shares of common stock and 500,000 warrants to the Plaintiff, make an initial payment of $33,503 by December 4, 2019 and beginning on December 16, 2019, the Company will make payments of $10,000 per month for 10 months in full satisfaction of the Separation Agreement and General Release originally entered into on July 21, 2017. The Company has paid this liability in full as of September 11, 2020.

Commitment

Commitment	12 Months Ended
Commitment	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitment	NOTE 10: COMMITMENT On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021. Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $180,000. Additionally, in December 2020, Dr. Korenko satisfied the conditions to have his deferred compensation as discussed in the Employment Agreement paid to him.

Concentrations of Credit and Ot

Concentrations of Credit and Other Risks	12 Months Ended
Concentrations of Credit and Other Risks	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Concentrations of Credit and Other Risks	NOTE 11: CONCENTRATIONS OF CREDIT AND OTHER RISKS Accounts Receivable The Company had one customer that represented 100% of the Company’s total revenues for the years ended December 31, 2020 and 2019. The customer that represented 100% of the Company’s total revenue as of December 31, 2020 and 2019 had no net accounts receivable balances. The loss of a significant customer representing the percentage of total revenue would have a temporary adverse effect on the Company’s revenue, which would continue until the Company located new customers to replace them. The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary. As of December 31, 2020 and 2019, the Company had no allowance or bad debt expense recorded. Product Purchases Some of the products the Company might market and components thereof are currently available only from a limited number of suppliers including the source for the main component in the Company’s products, Y-90 which is only derived from one source. Failure to obtain deliveries from this source could have a material adverse effect on the Company’s ability to operate.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12: SUBSEQUENT EVENTS In January 2021, the Company issued 1,259,250 shares of common stock in conversion of a convertible note payable of $50,000 and accrued interest of $370. This conversion resulted in a loss on conversion of $176,295. In January 2021, the Company issued 3,423,968 shares of common stock in the cashless exercise of 4,875,000 warrants. In March 2021, the Company received $1,360,000 as part of their amended Regulation A+ at $0.08 (17,000,000 shares), along with the sale of 8,487,500 two-year warrants at a strike price of $0.10 per share for $8,238.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Financial Statement Reclassification	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these audited financial statements so as to conform to current period classifications.
Cash Equivalents	Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2020 and 2019, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.
Derivative Liabilities and Beneficial Conversion Feature	Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date.
Fixed Assets	Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.
License Fees	License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%). Future minimum royalties for the years ended December 31 are noted below: Minimum Royalties per Calendar Year Calendar Year 2021 $ 10,000 2022 4,000 Total $ 14,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The 2021 fee was paid in December 2020.
Patents and Intellectual Property	Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the years ended December 31, 2019 and 2018, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. The Company recognized revenue as they (i) identified the contracts with ach customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue generated during the years ended December 31, 2020 and 2019 related to sales of product.
Loss Per Share	Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2020 and 2019, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2020 and 2019, which include the following: December 31, 2020 December 31, 2019 Convertible debt 1,252,456 10,914,782 Preferred stock 12,998,195 27,372,515 Common stock options 28,885,461 34,524,580 Common stock warrants 32,064,375 31,286,847 Total potential dilutive securities 75,190,487 104,098,724
Research and Development Costs	Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $84,668 and $67,584 research and development costs for the years ended December 31, 2020 and 2019, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the years then ended.
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2020 and 2019, the Company incurred $6,182 and $0 in advertising and marketing costs which are included in general and administrative expenses.
Contingencies	Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2020 and 2019.
Income Taxes	Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2020 and 2019. The Company did not have any deferred tax liability or asset on its balance sheet on December 31, 2020 and 2019. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2020 and 2019, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. The Company has determined that no amounts had to be revalued upon adoption of this amendment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Depreciation Estimated Useful Life	Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years
Schedule of Future Minimum Royalties	Future minimum royalties for the years ended December 31 are noted below: Minimum Royalties per Calendar Year Calendar Year 2021 $ 10,000 2022 4,000 Total $ 14,000
Schedule of Dilutive Earnings Per Share	The following represent common stock equivalents that could be dilutive in the future as of December 31, 2020 and 2019, which include the following: December 31, 2020 December 31, 2019 Convertible debt 1,252,456 10,914,782 Preferred stock 12,998,195 27,372,515 Common stock options 28,885,461 34,524,580 Common stock warrants 32,064,375 31,286,847 Total potential dilutive securities 75,190,487 104,098,724

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
Fixed Assets (Tables)	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Production equipment $ - $ - Less accumulated depreciation - - $ - $ -

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Transaction	As of December 31, 2020 and 2019, the Company had the following related party convertible notes outstanding: 2020 2019 September 2019 $15,000 Note, 8% interest, due January 2020 $ - $ 15,000 - - Total Convertible Notes Payable, Net $ - $ 15,000 Less: Debt Discount - (500 ) $ - $ 14,500 As of December 31, 2020 and 2019, the Company had the following related party notes outstanding: 2020 2019 January 2019 $60,000 Note, 8% interest, due January 2020 $ 60,000 $ 60,000 March 2019 $48,000 Note, 8% interest, due March 2020 48,000 48,000 April 2019 $29,000 Note, 8% interest, due April 2020 29,000 29,000 July 2019 $50,000 Note 8% interest, due July 2020 50,000 50,000 November 2019 $50,000 Note 8% interest, due November 2020 50,000 50,000 Total Related Party Notes Payable, Net $ 237,000 $ 237,000

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
Convertible Notes Payable (Tables)	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	As of December 31, 2020 and 2019, the Company had the following convertible notes outstanding: 2020 2019 July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 45,000 May 2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019 - 60,000 July 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 38,000 September 2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 25,000 September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 50,000 September 2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 - 37,000 December 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due March 31, 2020 - 50,000 November 2020 $50,000 Note convertible into common shares at $0.04, 6% interest, due May 30, 2021 50,000 - Penalties on notes in default 12,418 10,618 Total Convertible Notes Payable, Net $ 107,418 $ 465,618 Less: BCF Discount - (6,187 ) Less: Debt Discount - (24,545 ) $ 107,418 $ 434,886

Promissory Notes Payable (Table

Promissory Notes Payable (Tables)	12 Months Ended
Promissory Notes Payable (Tables)	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Promissory Notes Payable, Net	As of December 31, 2020 and 2019, the Company had the following promissory notes outstanding: 2020 2019 February 2019, two promissory notes for $50,000 each (total of $100,000), maturing August 2019, extended to February 2020, at 8.00% interest (originally) and now 15% interest and extended to August 20, 2020 $ - $ 100,000 Debt discount (- ) - Total Promissory Notes Payable, Net $ - $ 100,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Net Deferred Tax Assets	Net deferred tax assets consist of the following components as of December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Deferred tax assets: Net operating loss carryover $ 6,080,000 $ 5,890,000 Interest expense - 15,000 Related party accrual 6,400 23,400 Capital Loss Carryover 3,400 3,400 Deferred tax liabilities Depreciation (- ) (2,100 ) Valuation allowance (6,089,800 ) (5,929,700 ) Net deferred tax asset $ - $ -
Schedule of Federal Income Tax Rate	The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2020 and 2019 due to the following: December 31, 2020 December 31, 2019 Book income (loss) $ (201,000 ) $ (338,100 ) Forgiveness of debt (600 ) (7,200 ) Depreciation (1,100 ) (1,100 ) Interest expense - 15,000 Related party accrual 4,000 21,100 Stock for services - 2,600 Options expense 500 134,000 Non-cash interest expense 5,900 39,900 Valuation allowance 192,300 133,800 Income tax expense $ - $ -

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
Stockholders' Deficit (Tables)	Dec. 31, 2020
Equity [Abstract]
Schedule of Changes in Stock Option	The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2018 11,318,021 $ 0.11-120.00 3.91 years $ - $ 0.24 Options granted 23,252,809 $ 0.024-0.04 - $ - Options exercised - $ - - $ - Options expired (46,250 ) $ - - $ - Balance at December 31, 2019 34,524,580 $ 0.024-120.00 6.49 years $ 277,973 $ 0.08 Options granted - $ - - $ - Options exercised (2,500,000 ) $ - - $ - Options expired (3,139,119 ) $ - - $ - Balance at December 31, 2020 28,885,461 $ 0.024-120.00 5.57 years $ 1,661,429 $ 0.05 Exercisable at December 31, 2020 28,789,836 $ 0.024-120.00 5.56 years $ 1,653,636 $ 0.05
Schedule of Changes in Common Stock Warrants	The following schedule summarizes the changes in the Company’s common stock warrants: Weighted Weighted Warrants Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2018 23,052,472 $ 0.08-80.00 1.77 years $ - $ 0.08 Warrants granted 8,234,375 $ - - $ Warrants exercised - $ - - $ Warrants expired/cancelled - $ - - $ Balance at December 31, 2019 31,286,847 $ 0.08-80.00 0.97 years $ - $ 0.10 Warrants granted 31,870,000 $ 0.045-0.06 - $ Warrants exercised/exchanged (8,727,500 ) $ - - $ Warrants expired/cancelled (22,364,972 ) $ - - $ Balance at December 31, 2020 32,064,375 $ 0.04-80.00 1.65 years $ 1,614,567 $ 0.06 Exercisable at December 31, 2020 32,064,375 $ 0.04-80.00 1.65 years $ 1,614,567 $ 0.06
Schedule of Changes in Restricted Stock Units	The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2018 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at December 31, 2019 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at December 31, 2020 262,500 $ 0.59
Schedule of Assumptions Used in Fair Value Measurement	The following assumptions were used for the years ended December 31, 2020 and 2019: Year Ended Year Ended December 31, December 31, Expected term 2 - 5 years 2 - 5 years Expected volatility 109 - 147 % 144 - 295 % Expected dividend yield - - Risk-free interest rate 0.20 - 0.58 % 0.58 – 0.81 %

Organization & Basis of Prese_2

Organization & Basis of Presentation (Details Narrative) - USD ($)	Dec. 03, 2020	Dec. 02, 2020	Jun. 10, 2020	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Jun. 03, 2020	Apr. 30, 2020
Common stock, shares authorized					950,000,000	950,000,000
Common stock, par value					$ 0.001	$ 0.001
Preferred stock, shares authorized					20,000,000	20,000,000
Preferred stock, par value					$ 0.001	$ 0.001
Current operation activities					$ 2,000,000
Cash on hand					903,704	$ 20,381
Proceeds from convertible note				$ 497,880	150,000	500,000
Convertible note payable					107,418	465,618		$ 15,000
Proceeds from issuance of common stock	$ 1,138,800	$ 1,138,800				50,000
Shares issued during period					1,636,680	100,000
Proceeds from issuance of warrant	19,200	$ 19,200
Required amount for maintain current operating activities					2,000,000
12 to 24 months [Member]
Required amount for maintain current operating activities					9,000,000
Common Stock [Member]
Shares issued during period	$ 42,177,778				$ 60,618	$ 1,250
Warrant [Member]
Shares sold	19,200,000
Note Agreements [Member]
Convertible note payable							$ 525,000
Accrued interest							27,536
Exchange premium stipulated							$ 98,508
First Tranche [Member]
Offering term			The intent is to raise up to $4,050,000 over the next 12-18 months, which may be completed in separate closings.
First Tranche [Member] \| Maximum [Member] \| 12 to 18 months [Member]
Proceeds from stock offering			$ 1,800,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Production equipment capitalized cost	$ 2,500
Fixed assets capitalized cost	1,500
Nonrefundable license fee	$ 17,500
Royalties percentage, description	The increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%).
Economic life of the patent	10 years
Research and development costs	$ 84,668	$ 67,584
Advertising and marketing costs	$ 6,182	$ 0
Significant Change in Unrecognized Tax Benefits	The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Depreciation Estimated Useful Life (Details)	12 Months Ended
	Dec. 31, 2020
Production Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	3 years
Production Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	7 years
Office Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Office Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Future Minimum Royalties (Details)	Dec. 31, 2020USD ($)
Accounting Policies [Abstract]
2021	$ 10,000
2022	4,000
Total	$ 14,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Dilutive Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	75,190,487	104,098,724
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	1,252,456	10,914,782
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	12,998,195	27,372,515
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	28,885,461	34,524,580
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	32,064,375	31,286,847

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
Fixed Assets (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Depreciation expense
Piece of Equipment [Member]
Property, Plant and Equipment [Line Items]
Proceeds from sale of equipment	$ 0
Equipment value	$ 0

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - Production Equipment [Member] - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Production equipment
Less accumulated depreciation
Net fixed assets

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Dec. 10, 2020

Sep. 24, 2019

Apr. 29, 2019

Mar. 27, 2019

Feb. 20, 2019

Jan. 24, 2019

Apr. 30, 2020

Dec. 31, 2020

Nov. 25, 2020

Dec. 31, 2019

Dec. 02, 2020

Mar. 31, 2020

Nov. 25, 2019

Aug. 20, 2019

Jul. 05, 2019

Related Party Transaction [Line Items]

Advances from related party

$ 237,000

Debt instrument interest rate

8.00%

Note maturity date

Aug. 20,
2019

Proceeds from warrants

19,200,000

750,000

Debt discount

24,545

Notes payable to related party

237,000

Accrued interest payable

$ 619

68,021

75,166

Related party payables

32,110

Conversion shares issued

Convertible note payable

15,000

107,418

465,618

Debt conversion, amount converted

$ 3,124

$ 701,044

Debt conversion, shares issued

694,178

Number of share options exercised

2,500,000

Director [Member]

Related Party Transaction [Line Items]

Debt instrument interest rate

8.00%

Note maturity date

Jul. 5,
2020

Mar. 27,
2020

Jan. 24,
2020

Nov. 25,
2020

Interest expenses, related party

$ 18,960

$ 11,307

Notes payable to related party

$ 29,000

$ 48,000

$ 60,000

$ 50,000

Debt term

1 year

Accrued interest payable

30,267

CEO [Member]

Related Party Transaction [Line Items]

Related party payables

$ 107,000

Chairman [Member] | April 2020 [Member]

Related Party Transaction [Line Items]

Conversion shares issued

385,302

Convertible Notes Payable [Member]

Related Party Transaction [Line Items]

Interest expenses, related party

$ 298

321

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Advances from related party

20,000

Repayment of advance from related party

$ 5,000

Advances from related party, outstanding balance

$ 15,000

Debt instrument interest rate

8.00%

12.50%

Note maturity date

Jan. 15,
2020

Proceeds from warrants

150,000

Debt instrument description

The Company recognized a discount on the convertible note of $3,721 as a result of the warrants which are being amortized over the life of the note through January 15, 2020.

Debt discount

$ 3,721

Number of share options exercised

2,500,000

Stock options exercised

$ 60,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transaction (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	$ 237,000	$ 237,000
Total Convertible Notes Payable, Net	107,418	434,886
Less: Debt Discount		(24,545)
Related Party Notes Payable [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	237,000	237,000
Total Convertible Notes Payable, Net		15,000
Less: Debt Discount		(500)
Convertible Notes Payable		14,500
Related Party Notes Payable [Member] \| Related Party [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net		15,000
Related Party Notes Payable [Member] \| Related Party One [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	60,000	60,000
Related Party Notes Payable [Member] \| Related Party Two [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	48,000	48,000
Related Party Notes Payable [Member] \| Related Party Three [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	29,000	29,000
Related Party Notes Payable [Member] \| Related Party Four [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	50,000	50,000
Related Party Notes Payable [Member] \| Related Party Five [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	$ 50,000	$ 50,000

Related Party Transactions - _2

Related Party Transactions - Schedule of Related Party Transaction (Details) (Parenthetical) - USD ($)	1 Months Ended
	Nov. 30, 2019	Sep. 30, 2019	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Feb. 20, 2019
Related Party Transaction [Line Items]
Debt instrument, face amount							$ 100,000
Note, interest rate							8.00%
Related Party Notes Payable [Member] \| Related Party [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount						$ 15,000
Note, interest rate						8.00%
Note due date, description						January 2020
Related Party Notes Payable [Member] \| Related Party One [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount					$ 60,000
Note, interest rate					8.00%
Note due date, description					January 2020
Related Party Notes Payable [Member] \| Related Party Two [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount				$ 48,000
Note, interest rate				8.00%
Note due date, description				March 2020
Related Party Notes Payable [Member] \| Related Party Three [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount			$ 29,000
Note, interest rate			8.00%
Note due date, description			April 2020
Related Party Notes Payable [Member] \| Related Party Four [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount	$ 50,000
Note, interest rate	8.00%
Note due date, description	July 2020
Related Party Notes Payable [Member] \| Related Party Five [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount		$ 50,000
Note, interest rate		8.00%
Note due date, description		November 2020

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)

Nov. 30, 2020

Sep. 30, 2019

Aug. 20, 2019

Jul. 31, 2019

May 31, 2019

Feb. 20, 2019

Jan. 31, 2020

Jun. 30, 2020

Dec. 31, 2020

Dec. 31, 2019

Dec. 28, 2020

Apr. 30, 2020

Jul. 31, 2012

Debt Instrument [Line Items]

Convertible note payable

$ 107,418

$ 465,618

$ 15,000

Debt discount

24,545

Debt maturity date

Aug. 20,
2019

Debt instrument interest rate

8.00%

Proceeds from convertible debt

$ 497,880

150,000

500,000

Number of warrants issued

6,860,000

Warrant [Member]

Debt Instrument [Line Items]

Warrant exchange shares

1,867,500

6,860,000

Two Noteholders [Member]

Debt Instrument [Line Items]

Debt maturity date

Aug. 20,
2020

Accredited Investor [Member]

Debt Instrument [Line Items]

Debt maturity date

Mar. 31,
2020

Debt instrument interest rate

8.00%

Warrants exercise price

$ 0.06

Warrants term

2 years

Proceeds from issuance of convertible note

$ 100,000

Number of warrants granted

1,250,000

Accredited Investor [Member] | Warrant [Member]

Debt Instrument [Line Items]

Debt maturity date

Mar. 31,
2022

Number of warrants granted

1,312,500

Convertible Note Payable [Member]

Debt Instrument [Line Items]

Interest expenses

$ 21,934

16,563

Conversion price per share

$ 4.60

Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Convertible note payable

$ 50,000

$ 300,000

$ 50,000

Debt discount

$ 10,000

Debt maturity date

Jan. 15,
2020

Mar. 31,
2020

Debt instrument interest rate

6.00%

8.00%

12.50%

8.00%

Conversion price per share

$ 0.04

$ 0.032

$ 0.04

Proceeds from convertible debt

$ 250,000

Shares issued price per share

$ 1.20

Number of warrants issued

625,000

Warrants exercise price

$ 0.06

Warrants term

2 years

Fair value of warrants

$ 14,299

Debt instrument, description

Amended to $0.045 per share

Warrant exchange shares

1,867,500

Conversion of common shares

933,750

Convertible Promissory Note [Member] | Qualified Financing [Member]

Debt Instrument [Line Items]

Debt maturity date

May 30,
2021

Oct. 30,
2019

Proceeds from convertible debt

$ 350,000

$ 250,000

Convertible Promissory Note [Member] | Qualified Financing [Member] | Note Holders [Member]

Debt Instrument [Line Items]

Shares issued price per share

$ 1.20

Number of warrants issued

625,000

Warrants exercise price

$ 0.04

Warrants term

2 years

Fair value of warrants

$ 12,592

Warrant exchange shares

1,867,500

Conversion of common shares

933,750

Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member]

Debt Instrument [Line Items]

Proceeds from convertible debt

$ 250,000

Shares issued price per share

$ 1.20

Number of warrants issued

3,000,000

Warrants term

2 years

Fair value of warrants

$ 91,716

Debt instrument, description

Amended to $0.045 per share

Debt instrument beneficial conversion feature

$ 59,957

Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member] | Minimum [Member]

Debt Instrument [Line Items]

Warrants exercise price

$ 0.06

Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member] | Maximum [Member]

Debt Instrument [Line Items]

Warrants exercise price

$ 0.08

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2020	Apr. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Principal	$ 107,418	$ 15,000	$ 465,618
Penalties on notes in default principal (net)	12,418		10,618
Less: BCF Discount			(6,187)
Less: Debt Discount			(24,545)
Convertible notes payable, principal (net)	107,418		434,886
Convertible Notes Payable One [Member]
Debt Instrument [Line Items]
Principal	45,000		45,000
Convertible Notes Payable Two [Member]
Debt Instrument [Line Items]
Principal			60,000
Convertible Notes Payable Three [Member]
Debt Instrument [Line Items]
Principal			50,000
Convertible Notes Payable Four [Member]
Debt Instrument [Line Items]
Principal			50,000
Convertible Notes Payable Five [Member]
Debt Instrument [Line Items]
Principal			38,000
Convertible Notes Payable Six [Member]
Debt Instrument [Line Items]
Principal			25,000
Convertible Notes Payable Seven [Member]
Debt Instrument [Line Items]
Principal			50,000
Convertible Notes Payable Eight [Member]
Debt Instrument [Line Items]
Principal			50,000
Convertible Notes Payable Nine [Member]
Debt Instrument [Line Items]
Principal			37,000
Convertible Notes Payable Ten [Member]
Debt Instrument [Line Items]
Principal			50,000
Convertible Notes Payable Eleven [Member]
Debt Instrument [Line Items]
Principal	$ 50,000

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Dec. 31, 2019	Sep. 30, 2019	Sep. 30, 2019	Jul. 31, 2019	May 31, 2019	Aug. 31, 2012	Jul. 31, 2012	Nov. 30, 2020	Nov. 30, 2019	Feb. 20, 2019
Debt Instrument [Line Items]
Debt instrument, face amount										$ 100,000
Convertible Note Payable [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 1,060,000
Debt conversion price per share							$ 4.60
Debt interest rate							12.00%
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt maturity date description							December 2013
Convertible Notes Payable One [Member]
Debt Instrument [Line Items]
Debt instrument, face amount						$ 1,060,000
Debt conversion price per share						$ 4.60
Debt interest rate						12.00%
Debt maturity date description						January 2014
Convertible Notes Payable Two [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					$ 60,000
Debt conversion price per share					$ 0.04
Debt interest rate					8.00%
Debt maturity date description					October 30, 2019
Convertible Notes Payable Three [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 50,000
Debt conversion price per share				$ 0.04
Debt interest rate				8.00%
Debt maturity date description				January 15, 2020
Convertible Notes Payable Four [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 50,000	$ 50,000
Debt conversion price per share		$ 0.04	$ 0.04
Debt interest rate		8.00%	8.00%
Debt maturity date description			January 15, 2020
Convertible Notes Payable Five [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 38,000	$ 38,000
Debt conversion price per share		$ 0.04	$ 0.04
Debt interest rate		8.00%	8.00%
Debt maturity date description		January 15, 2020
Convertible Notes Payable Six [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 25,000	$ 25,000
Debt conversion price per share		$ 0.04	$ 0.04
Debt interest rate		8.00%	8.00%
Debt maturity date description			January 15, 2020
Convertible Notes Payable Seven [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 50,000	$ 50,000
Debt conversion price per share		$ 0.04	$ 0.04
Debt interest rate		8.00%	8.00%
Debt maturity date description			January 15, 2020
Convertible Notes Payable Eight [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 50,000	$ 50,000
Debt conversion price per share		$ 0.04	$ 0.04
Debt interest rate		8.00%	8.00%
Debt maturity date description			January 15, 2020
Convertible Notes Payable Nine [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 37,000	$ 37,000
Debt conversion price per share		$ 0.04	$ 0.04
Debt interest rate		8.00%	8.00%
Debt maturity date description			January 15, 2020
Convertible Notes Payable Ten [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 50,000
Debt conversion price per share	$ 0.04
Debt interest rate	8.00%
Debt maturity date description	March 31, 2020
Convertible Notes Payable Eleven [Member]
Debt Instrument [Line Items]
Debt instrument, face amount									$ 50,000
Debt conversion price per share									$ 0.04
Debt interest rate									6.00%
Debt maturity date description								May 30, 2021

Promissory Notes Payable (Detai

Promissory Notes Payable (Details Narrative) - USD ($)	Jul. 14, 2020	Aug. 20, 2019	Feb. 20, 2019	Apr. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 28, 2020	Dec. 02, 2020
Debt Instrument [Line Items]
Debt instrument, face amount			$ 100,000
Debt maturity date			Aug. 20, 2019
Debt instrument interest rate			8.00%
Number of warrants issued							6,860,000
Amortized debt discount					$ 53,527	$ 134,034
Number of warrants issued		750,000						19,200,000
Interest expense					287,471	261,374
Repayment of notes payable					50,000
Accrued interest payable				$ 619	68,021	75,166
Debt conversion, amount converted				$ 3,124	$ 701,044
Debt instrument converted into shares of common stock				694,178
Two Noteholders [Member]
Debt Instrument [Line Items]
Debt maturity date		Aug. 20, 2020
Two Noteholders [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate increase		8.00%
Two Noteholders [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate increase		15.00%
Noteholders One [Member]
Debt Instrument [Line Items]
Number of warrants issued		375,000
Noteholders Two [Member]
Debt Instrument [Line Items]
Number of warrants issued		375,000
Promissory Notes One [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 50,000
Promissory Notes Two [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 50,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Number of warrants issued					1,250,000
Fair value of warrants debt discount					$ 28,721
Amortized debt discount						28,721
Interest expense					$ 8,032	$ 9,410
Repayment of notes payable	$ 50,000
Accrued interest payable	13,442
Debt conversion, amount converted	$ 50,000
Debt instrument converted into shares of common stock	1,851,852

Promissory Notes Payable - Sche

Promissory Notes Payable - Schedule of Promissory Notes Payable, Net (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Debt discount		$ 24,545
Promissory Notes Payable [Member]
Promissory Notes Payable, Gross		100,000
Debt discount
Total Promissory Notes Payable, Net		$ 100,000

Promissory Notes Payable - Sc_2

Promissory Notes Payable - Schedule of Promissory Notes Payable, Net (Details) (Parenthetical) - USD ($)	1 Months Ended
	Feb. 28, 2019	Feb. 20, 2019
Debt instrument, face amount		$ 100,000
Note, interest rate		8.00%
Promissory Notes Payable One [Member]
Debt instrument, face amount	$ 50,000
Promissory Notes Payable Two [Member]
Debt instrument, face amount	50,000
Promissory Notes Payable [Member]
Debt instrument, face amount	$ 100,000
Note due date, description	August 2019
Note, interest rate	8.00%
Debt instrument, interest rate increase	15.00%
Promissory Notes Payable [Member] \| Extended Maturity [Member]
Note due date, description	extended to February 2020
Promissory Notes Payable [Member] \| Extended Maturity One [Member]
Note due date, description	extended to August 20, 2020

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Dec. 31, 2020USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 28,960,300

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryover	$ 6,080,000	$ 5,890,000
Interest expense		15,000
Related party accrual	6,400	23,400
Capital Loss Carryover	3,400	3,400
Deferred tax liabilities Depreciation		(2,100)
Valuation allowance	(6,089,800)	(5,929,700)
Net deferred tax asset

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Book income (loss)	$ (201,000)	$ (338,100)
Forgiveness of debt	(600)	(7,200)
Depreciation	(1,100)	(1,100)
Interest expense		15,000
Related party accrual	4,000	21,100
Stock for services		2,600
Options expense	500	134,000
Non-cash interest expense	5,900	39,900
Valuation allowance	192,300	133,800
Income tax expense

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Dec. 29, 2020	Dec. 28, 2020	Dec. 10, 2020	Dec. 03, 2020	Dec. 03, 2020	Dec. 02, 2020	Dec. 02, 2020	Nov. 30, 2020	Sep. 30, 2019	Sep. 24, 2019	Jul. 31, 2019	Jun. 21, 2019	Mar. 28, 2019	Feb. 20, 2019	Apr. 30, 2020	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Oct. 31, 2018	Jun. 30, 2015	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Aug. 20, 2019	May 31, 2019	Mar. 27, 2019	Oct. 08, 2018	Mar. 31, 2016
Class of Stock [Line Items]
Common stock shares authorized																	950,000,000										950,000,000	950,000,000
Common stock par value																	$ 0.001										$ 0.001	$ 0.001
Common stock shares issued		4,759,435				42,177,778	42,177,778										184,845,821										292,278,591	184,845,821
Common stock shares outstanding																	184,845,821										292,278,591	184,845,821
Preferred stock shares authorized																	20,000,000										20,000,000	20,000,000
Preferred stock par value																	$ 0.001										$ 0.001	$ 0.001
Gross proceeds from preferred stock																												$ 50,000
Number of shares issued, value																											1,636,680	100,000
Number of warrants issued						19,200,000	19,200,000																						750,000
Debt discount																											53,527	134,034
Debt instrument, face amount														$ 100,000
Accrued interest															$ 619		$ 75,166										68,021	75,166
Stock issued during the period converted
Debt instrument converted into shares of common stock															694,178
Debt conversion, amount converted															$ 3,124												701,044
Proceeds from issuance of common stock				$ 1,138,800		$ 1,138,800																						$ 50,000
Proceeds from issuance of warrant				$ 19,200		$ 19,200
Stock issued during period, stock options exercised, share																											2,500,000
Warrant to purchase of common stock		6,860,000
Stock issued for accounts payable and accrued expenses, shares																					1,062,500
Stock issued for accounts payable and accrued expenses																					$ 43,900
Number of stock issued for services																					312,500
Number of stock issued for services, value																					$ 12,500							$ 12,500
Number of shares issued in conversion of vested restricted stock units																					385
Number of stock options expired																											3,139,119	46,250
Number of stock options expired, value																										$ 2,176		$ 6,529
Recognized a gain on this transaction																												34,106
Stock based compensation																											$ 2,176	608,588
Debt discount																	$ 24,545											24,545
Interest expense																											287,471	261,374
Debt instrument, interest rate														8.00%
Debt instrument, maturity date														Aug. 20, 2019
Restricted Stock Units [Member]
Class of Stock [Line Items]
Stock based compensation																											0	$ 0
Expense yet to be recognized																											$ 155,400
Chief Executive Officer [Member]
Class of Stock [Line Items]
Number of warrants issued																	150,000											150,000
Stock issued during period, stock options exercised, share			2,500,000																								2,500,000
Stock issued during period, stock options exercised, value			$ 60,000																								$ 60,000
Debt discount																	$ 3,721											$ 3,721
Debt instrument, interest rate										8.00%							12.50%											12.50%
Debt instrument, maturity date										Jan. 15, 2020
Consultants [Member]
Class of Stock [Line Items]
Number of stock options issued																			382,500
Number of stock options expired												46,250
Consultant [Member]
Class of Stock [Line Items]
Number of stock options issued																	370,309
Options issued for settlement of accounts payable																	$ 14,812	$ 16,915
Shares issued for settlement of accounts payable, shares																		500,000
Settlement Agreement [Member]
Class of Stock [Line Items]
Number of stock options issued																		1,000,000
Option vesting period																		10 years
Options issued for settlement of accounts payable																		$ 33,829
Convertible Promissory Note [Member]
Class of Stock [Line Items]
Conversion price per share								$ 0.04	$ 0.04		$ 0.04						$ 0.04	$ 0.04										$ 0.04		$ 0.032
Conversion of preferred stock into common stock, shares								933,750
Warrant terms																	2 years											2 years
Warrant exercise price																	$ 0.06											$ 0.06
Convertible promissory note																									$ 651,044	651,044
Debt instrument, face amount																									525,000	525,000
Accrued interest																									$ 27,536	$ 27,536
Debt instrument converted into shares of common stock																								1,851,852
Debt conversion, amount converted																								$ 50,000
Class of warrant or right exchange								1,867,500
Warrant to purchase of common stock																	625,000											625,000
Debt discount																														$ 10,000
Debt instrument, interest rate								6.00%	8.00%		8.00%						8.00%	8.00%									12.50%	8.00%		8.00%
Debt instrument, maturity date									Jan. 15, 2020		Jan. 15, 2020																	Mar. 31, 2020
Common Stock [Member]
Class of Stock [Line Items]
Conversion of preferred stock into common stock, shares																5,449,875
Number of shares issued		4,759,435						933,750													18,390,225				18,440,000
Number of shares issued, value																									$ 497,880
Number of warrants issued																									9,220,000	9,220,000
Warrant terms																									2 years	2 years
Warrant exercise price																									$ 0.045	$ 0.045
Number of warrants issued, value																									$ 8,143	$ 8,143
Common Stock [Member] \| Note Agreement [Member]
Class of Stock [Line Items]
Conversion of preferred stock into common stock, shares																									21,770,668
Number of warrants issued																									2,200,000	2,200,000
Warrant terms																									2 years	2 years
Warrant exercise price																									$ 0.045	$ 0.045
Warrant expense																									$ 77,883
Stock issued during the period converted																									$ 98,508
Warrant [Member]
Class of Stock [Line Items]
Class of warrant or right exchange		6,860,000						1,867,500
Warrants expired																											22,364,972
Warrant [Member] \| Note Agreement [Member]
Class of Stock [Line Items]
Number of warrants issued																									4,400,000	4,400,000
Warrant exercise price																									$ 0.045	$ 0.045
Warrant expiration																									Mar. 31, 2022	Mar. 31, 2022
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																	5,000,000					5,000,000					5,000,000	5,000,000				5,000,000
Preferred stock par value																																$ 0.001
Preferred stock, liquidation preference per share																						$ 1
Conversion price per share																						$ 0.08
Voting percentage																						Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage																						100.00%
Payment to redemption of preferred stock																$ 50,000
Number of shares redeemable																100,000
Number of shares issued upon conversion																					1,471,218
Preferred shares exchange																					821,292
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																	5,000,000			5,000,000							5,000,000	5,000,000			5,000,000
Preferred stock par value																															$ 0.001
Preferred stock, liquidation preference per share																				$ 1
Conversion price per share																				$ 0.08
Voting percentage																				Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage																				100.00%
Conversion of preferred stock into common stock, shares																435,990
Number of shares issued																					821,292
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																	5,000,000						2,500,000				5,000,000	5,000,000
Preferred stock, liquidation preference per share																							$ 5
Conversion price per share																							$ 4
Gross proceeds from preferred stock																							$ 5,000,000
Voting percentage																							Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage																							100.00%
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock redeemed or called during period, shares							381,635
Stock redeemed or called during period, value							$ 13,650
Series B Preferred Stock [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Conversion of preferred stock into common stock, shares	3,750,000				3,457,400
Minimum [Member] \| Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																																	2,500,000
Maximum [Member] \| Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																																	5,000,000
Board of Directors [Member]
Class of Stock [Line Items]
Reverse stock split													reverse 1-for-8 stock split
Board of Directors [Member] \| Minimum [Member]
Class of Stock [Line Items]
Common stock shares authorized													2,000,000,000
Board of Directors [Member] \| Maximum [Member]
Class of Stock [Line Items]
Common stock shares authorized													950,000,000
Holder [Member] \| Series B Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of preferred stock into common stock, shares	300,000				276,592
Accredited Investors [Member]
Class of Stock [Line Items]
Proceeds from equity financing																					$ 100,000
Accredited Investors [Member] \| Warrant [Member]
Class of Stock [Line Items]
Warrant to purchase of common stock																					1,250,000						1,250,000
Debt discount																											$ 151,048
Number of warrants granted																											5,650,000
Accredited Investors [Member] \| Warrant [Member] \| Consulting Service [Member]
Class of Stock [Line Items]
Number of stock issued for services																											84,375
Number of stock issued for services, value																											$ 3,792
Shares issued for settlement of accounts payable, shares																											500,000
Number of warrants granted																											750,000
Interest expense																											$ 25,656
Shres issued for settlement of accounts payable																											$ 18,500
Accredited Investors [Member] \| Convertible Notes [Member]
Class of Stock [Line Items]
Number of warrants issued																	1,250,000											1,250,000
Warrant exercise price																	$ 0.06											$ 0.06
Debt instrument, face amount																	$ 100,000											$ 100,000
Debt instrument, interest rate																	8.00%											8.00%
Accredited Investors [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued																					1,250,000
Accredited Investors [Member] \| Warrant [Member] \| Convertible Notes [Member]
Class of Stock [Line Items]
Number of warrants issued																	1,312,500											1,312,500
Debt discount																												$ 28,482
Debt instrument, maturity date																												Mar. 31, 2020
Accredited Investors [Member] \| Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares issued																					100,000
Dr. Korenko [Member] \| Omnibus Securities and Incentive Plan [Member]
Class of Stock [Line Items]
Number of stock options issued																											21,000,000
Stock options vesting period description																											The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019, and December 31, 2019); (ii) 25% upon the Company filing a patent (completed on July 1, 2019); and (iii) 25% upon the first commercial sale of IsoPet®.
Fair value of options																											$ 585,144

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Changes in Stock Option (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Options Outstanding Beginning Balance	34,524,580	11,318,021
Number of Options granted		23,252,809
Number of Options exercised	(2,500,000)
Number of Options expired	(3,139,119)	(46,250)
Number of Shares Options Outstanding Ending Balance	28,885,461	34,524,580
Number of Shares Options Exercisable	28,789,836
Exercise Price Per Share exercised
Exercise Price Per Share expired
Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning	6 years 5 months 27 days	3 years 10 months 28 days
Weighted Average Remaining Contractual Life (in years) Outstanding, Ending	5 years 6 months 25 days	6 years 5 months 27 days
Weighted Average Remaining Contractual Life (in years) Exercisable	5 years 6 months 21 days
Aggregate Intrinsic Value Outstanding Beginning	$ 277,973
Aggregate Intrinsic Value Outstanding Ending	1,661,429	$ 277,973
Aggregate Intrinsic Value Exercisable	$ 1,653,636
Weighted Average Exercise Price Per Share Outstanding Beginning	$ 0.08	$ 0.24
Weighted Average Exercise Price Per Share Options granted
Weighted Average Exercise Price Per Share Options exercised
Weighted Average Exercise Price Per Share Options expired
Weighted Average Exercise Price Per Share Outstanding Ending	0.05	0.08
Weighted Average Exercise Price Per Share Exercisable	0.05
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	0.024	0.11
Exercise Price Per Share granted		0.24
Exercise Price Per Share exercised
Exercise Price Per Share expired
Exercise Price Per Share Outstanding Ending Balance	0.024	0.024
Exercise Price Per Share Exercisable	0.024
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	120	120
Exercise Price Per Share granted		0.04
Exercise Price Per Share exercised
Exercise Price Per Share expired
Exercise Price Per Share Outstanding Ending Balance	120	$ 120
Exercise Price Per Share Exercisable	$ 120

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Changes in Common Stock Warrants (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Warrants Outstanding Beginning	31,286,847	23,052,472
Number of Shares, Warrants granted	31,870,000	8,234,375
Number of Shares, Warrants exercised	(8,727,500)
Number of Shares, Warrants expired/cancelled	(22,364,972)
Number of Shares, Warrants Outstanding Ending	32,064,375	31,286,847
Number of Shares, Warrants Exercisable Ending	32,064,375
Exercise Price Per Share Warrants granted
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	11 months 19 days	1 year 9 months 7 days
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	1 year 7 months 24 days	11 months 19 days
Weighted Average Remaining Contractual Life Warrants Exercisable	1 year 7 months 24 days
Aggregate Intrinsic Value Outstanding Beginning
Aggregate Intrinsic Value Outstanding Ending	1,614,567
Aggregate Intrinsic Value Exercisable	$ 1,614,567
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning	$ 0.10	$ 0.08
Weighted Average Exercise Price Per Share Exercise Price Warrants granted
Weighted Average Exercise Price Per Share Exercise Price Warrants exercised
Weighted Average Exercise Price Per Share Exercise Price Warrants expired/cancelled
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending	0.06	0.10
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable	0.06
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	0.08	0.08
Exercise Price Per Share Warrants granted	0.045
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Exercise Price Per Share Warrants Outstanding Ending	0.04	0.08
Exercise Price Per Share Exercisable	0.04
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	80	80
Exercise Price Per Share Warrants granted	0.06
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Exercise Price Per Share Warrants Outstanding Ending	80	$ 80
Exercise Price Per Share Exercisable	$ 80

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Assumptions Used in Fair Value Measurement (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	109.00%	144.00%
Expected volatility, maximum	147.00%	295.00%
Expected dividend yield
Risk-free interest rate, minimum	0.20%	0.58%
Risk-free interest rate, maximum	0.58%	0.81%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	2 years	2 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years	5 years

Stockholders' Deficit - Sched_4

Stockholders' Deficit - Schedule of Changes in Restricted Stock Units (Details) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, RSU's Outstanding Beginning	262,500	262,500
Number of Shares, RSU's granted
Number of Shares, RSU's vested
Number of Shares, RSU's forfeited
Number of Shares, RSU's Outstanding Ending	262,500	262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning	$ 0.59	$ 0.59
Weighted Average Grant Date Fair Value, RSU's granted
Weighted Average Grant Date Fair Value, RSU's vested
Weighted Average Grant Date Fair Value, RSU's forfeited
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending	$ 0.59	$ 0.59

Legal Matters (Details Narrativ

Legal Matters (Details Narrative) - USD ($)	Dec. 16, 2019	Dec. 04, 2019	Nov. 25, 2019	Dec. 02, 2020	Aug. 20, 2019
Number of warrants issued				19,200,000	750,000
Settlement Agreement [Member] \| Plaintiff [Member]
Number of shares issued			500,000
Number of warrants issued			500,000
Initial payment	$ 10,000	$ 33,503

Commitment (Details Narrative)

Commitment (Details Narrative) - Employment Agreement [Member] - Dr. Michael K. Korenko [Member]	Jun. 04, 2019USD ($)
Agreement term description	The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021.
Compensation amount	$ 180,000
Compensation payable description	Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $180,000.

Concentrations of Credit and _2

Concentrations of Credit and Other Risks (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Allowance for bad debt expense
Customer One[Member]
Accounts receivable
Customer One[Member] \| Revenue [Member]
Concentration risk percentage	100.00%	100.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 15, 2021	Dec. 03, 2020	Dec. 02, 2020	Jan. 31, 2021	Apr. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 28, 2020
Subsequent Event [Line Items]
Debt conversion, converted instrument, shares issued					694,178
Debt conversion, converted instrument, amount					$ 3,124	$ 701,044
Accrued interest					$ 619	68,021	75,166
Loss on conversion							$ (18,744)
Cashless exercise of warrants								6,860,000
Proceeds from issuance of warrants		$ 19,200	$ 19,200
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of common stock issued	17,000,000			3,423,968
Cashless exercise of warrants				4,875,000
Proceeds from sale of equity	$ 1,360,000
Price per share	$ 0.08
Number of warrants sold	8,487,500
Exercise price of warrants	$ 0.10
Proceeds from issuance of warrants	$ 8,238
Subsequent Event [Member] \| Convertible Notes [Member]
Subsequent Event [Line Items]
Debt conversion, converted instrument, shares issued				1,259,250
Debt conversion, converted instrument, amount				$ 50,000
Accrued interest				370
Loss on conversion				$ 176,295